3 Bio-Pharmaceuticals You Can’t Ignore: Arena Pharmaceuticals, Inc. (ARNA), VIVUS Inc. (VVUS)

Page 1 of 2

The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the SPDR S&P Biotech ETF (XBI) and iShares NASDAQ Biotechnology Index (IBB), giving returns of more than 20%. The entire industry is heavily dependent for growth on the approvals of the Food and Drug Administration (FDA). According to research by Bloomberg, this year the authority approved the most number of drug candidates in the last fifteen years. The FDA usually approves around 20-25 drugs every year, but this year an exceptional 39 drugs received the FDA nod.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

A number of micro/small-cap bio-pharmaceutical companies have benefited from FDA approvals in the last couple of years, and amongst them are Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amarin Corporation plc (ADR) (NASDAQ:AMRN) and VIVUS, Inc. (NASDAQ:VVUS). These companies have since seen depreciating stock prices due to their inability to convert promise into actual fundamental value. Despite investor backlash, I believe these stocks are worth following and still hold value for investors.

Amarin

Amongst the 3 stocks under discussion today, Amarin is the safest and surest bet. The company has received FDA approval for its Triglyceride lowering drug Vascepa, but is still waiting for a decision on its NCE status. This decision has been the primary hindrance to a much anticipated acquisition of the company and has forced the company management to commercialize Vascepa. Amarin looks to upset GlaxoSmithKline’s Lovaza, which generates sales of approximately a billion dollars every year. What makes Vascepa exciting is the fact that unlike Lovaza, Vascepa also decreases LDL levels. The increase in LDL has been one of the primary reason physicians have been somewhat reluctant to prescribe Lovaza. With this restriction removed, the sales potential of Vascepa can be huge.

Vivus

The large number of FDA approvals also included two obesity control drugs: Qsymia and Belviq. Qsymia has been approved for chronic weight management in addition to reduced calorie diet and exercise. The initial sales data for Qsymia has not been good, but recent reports show that Qsymia has started to gain some momentum. Company disclosures show that Qsymia sales have shown a growth of 68%, and there is a strong expectation that this growth might continue.

Recent research also indicates that use of Qsymia leads to improvements in blood pressure, triglycerides, and cholesterol of obese patients suffering from these issues. This can be another incentive for doctors who have been so far hesitant to prescribe Qsymia due to its after-effects. Despite these setbacks, there is little doubt that Vivus still has a lot of potential, especially considering the obesity epidemic in the United States.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!